hyperalgesia/zápal

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 77 výsledky

Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This is the national stage of International Application PCT/HU2014/000097, filed Oct. 28, 2014. FIELD OF THE INVENTION The present invention relates to 4-phenetylamino-7H-pyrrolo[2,3-d]pyrimidine derivatives of the general formula (I) and solvates, hydrates and pharmaceutically acceptable salts

Method of treatment or prophylaxis of inflammatory pain

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

FIELD OF THE INVENTION This invention relates generally to compounds that are useful in the prevention and amelioration of signs and symptoms associated with inflammatory pain. More particularly, the present invention relates to the use of angiotensin II receptor 2 (AT.sub.2 receptor) antagonists

Method of treatment or prophylaxis of inflammatory pain

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

PRIORITY DATA AND INCORPORATION BY REFERENCE This is a National Stage application under 35 U.S.C. 371 of International Application No. PCT/AU2007/000339, filed Mar. 20, 2007, which claims the benefit of priority to AU Application No. 2006901413 filed Mar. 20, 2006, the entireties of which are hereby

Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This is the national stage of International Application PCT/HU2014/000127, filed Dec. 18, 2014. TECHNICAL FILED OF THE INVENTION The present invention is based on potent analgesic (anti-hyperalgesic) effect of semicarbazide-sensitive amine oxidase (SSAO) also known as vascular adhesion protein 1

Compositions and methods for inhibition of phospholipase A2 mediated inflammation

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

FIELD OF THE INVENTION The present invention relates generally to the field of non-steroidal anti-inflammatory agents for inhibition of phospholipase A2 enzymes, and the use of such agents in controlling inflammation. BACKGROUND OF THE INVENTION Injury to one part of the body often results in

Use of precursors of tachykinins and/or their fragments in medical diagnostic

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

CROSS REFERENCE TO RELATED APPLICATIONS This application is a 371 filing of PCT International application no. PCT/EP2005/004254 filed Apr. 20, 2005 and published in English as WO 2005/103712 on Nov. 3, 2005 which claims the priority of European application no. 040009284.3 filed Apr. 20, 2004. The

Use of precursors of tachykinins and/or their fragments in medical diagnostic

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present invention relates to the use of protachykinin and/or its fragments and/or its splice variants, fragments comprising protachykinin and/or combinations thereof in medical diagnostics. In the following text all these molecules, fragments, combinations thereof etc. are referred to as

Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

FIELD OF INVENTION The present invention relates to spirochromane compounds of formula (I), which are useful for treating disorders caused by or exacerbated by vanilloid receptor type 1 (VR1) activity. The present invention also includes pharmaceutical compositions containing compounds of formula

Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Bradykinin receptor modulators and use thereof

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This application is the national stage entry under 35 U.S.C. .sctn. 371 of International Application No. PCT/IB2014/001162, filed on Jun. 24, 2014, which claims priority to Swiss Application No. 01168/13, filed Jun. 25, 2013. The contents of these applications are each incorporated herein by

Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

TECHNICAL FIELD OF THE INVENTION BACKGROUND OF THE INVENTION Nitric oxide (NO), which serves as an intracellular messenger, is implicated in a number of processes in the central nervous system. In the spinal cord, considerable evidence has demonstrated that NO contributes to the development of

Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

TECHNICAL FIELD OF THE FIELD INVENTION BACKGROUND OF THE INVENTION Nitric oxide (NO), which serves as an intracellular messenger, is implicated in a number of processes in the central nervous system. In the spinal cord, considerable evidence has demonstrated that NO contributes to the development of

Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF THE INVENTION Nitric oxide (NO), which serves as an intracellular messenger, is implicated in a number of processes in the central nervous system. In the spinal cord, considerable evidence has demonstrated that NO contributes to the development of hyperalgesia in models of acute and

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

TECHNICAL BACKGROUND The present invention relates to compounds of formula (I), which are useful for treating disorders caused by exacerbated by or vanilloid receptor activity, pharmaceutical compositions containing compounds of formula (I) and are useful in treating pain, bladder overactivity, and

Bradykinin B1 receptor antagonists

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

FIELD OF THE INVENTION The invention relates to pyrimidines, triazines, and anilines that are bradykinin B.sub.1 -receptor antagonists. The compounds are useful for treating diseases associated with inappropriate or excessive bradykinin receptor activity, such as diabetic vasculopathy, inflammation,

Predchádzajúce
1
2
3
4
5
6
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume